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Background: Besides dental erosion syndrome, other oral syndromes could benefit from the stimulation of sali-
vary secretion, in patients with gastro-oesophageal reflux disease (GORD). Our aims is evaluate the improvement 
of oral extra-oesophageal manifestations in patients with GORD using xylitol–malic acid tablets to stimulate 
salivary secretion.
Material and Methods: The effectiveness of salivary stimulation using xylitol–malic acid tablets (as a supplement 
to omeprazole 40 mg/day) was assessed in a clinical trial (n = 14) lasting six months with patients with prior posi-
tive pH-metry, through GORD extra-oesophageal clinical signs, GerdQ and RDQ questionnaires, odontological 
variables, basal salivary secretion, stimulated salivary secretion, pH and buffer capacity, mucosal erythema index 
and dental wear. Statistics: chi-square (Haberman post-hoc), ANOVA, and Mann-Whitney U; variables between 
visits were evaluated with McNemar’s Student’s t and Wilcoxon tests; p < 0.05.
Results: 100% of patients not taking xylitol–malic acid presented xerostomia, but only 14.3% of patients taking 
xylitol–malic acid (p < 0.01) did. The mean saliva-buffer capacity at the last visit for patients not taking xylitol–
malic acid was 2.14 ± 0.38, versus 2.71 ± 0.49 for patients taking xylitol–malic acid (p < 0.05). Retro-sternal burn-
ing (p < 0.05), heartburn (p < 0.05) and regurgitation (p < 0.05) were also reduced.
Conclusions: Xylitol–malic acid tablets improve quality of life among patients with GORD, by reducing dry 
mouth, increasing saliva buffering and reducing heartburn, retro-sternal burning and regurgitation.
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Introduction
Gastro-oesophageal reflux disease (GORD) is produced 
when reflux content from the stomach causes symptoms 
and/or complications (1). The reflux components that 
cause the most damage are acid and pepsin, although 
bile and pancreatic enzymes can also contribute to 
damage in some patients. GORD may or may not have 
typical symptoms, and it may manifest in patients with 
a normal oesophagus or with oesophagitis, but reflux 
episodes are abnormal in all cases (2).
Regarding the pathogenesis of GORD, many factors 
interact in different proportions, with the predominant 
factor varying by patient (e.g., defects in the anti-reflux 
barrier, defective oesophageal clearance, disorders of 
oesophageal mucosal resistance, increase in gastric acid 
secretion, delay in gastric emptying or circumstances in 
which intra-abdominal pressure increases) (1,3).
The typical reflux syndrome is characterized by the 
presence of heartburn and/or regurgitation. Heartburn 
is defined as a burning sensation in the retro-sternal 
area, while regurgitation is defined as perception in the 
mouth of or the hypopharynx of a flux from gastric con-
tent reflux. Apart from these 2 characteristic symptoms, 
patients may experience others, such as epigastric pain 
or difficulty falling asleep (1).
Lifestyle changes highly important from both the pa-
tient’s and the doctor’s perspective. Lifestyle changes 
can improve reflux symptoms in patients with slight to 
moderate GORD. Among these changes is diet control; 
avoiding food that can cause reflux is yet another thera-
peutic measure (4). Eating favours reflux episodes, eat-
ing slowly and going to bed at least 4 hours after meals 
appear to improve the clinical signs of GORD. Giving up 
smoking, losing weight, avoiding very tight clothing and 
raising one’s head during sleep are recommended (5,6). 
Lifestyle changes are often not enough; consequently, 
other therapeutic measures need to be resorted to (4).
A wide range of drugs are aimed at treating gastro-
esophageal reflux disease, such as alginates (sodium 
alginate), mucosal barrier protectors (sucralfate), pro-
kinetic agents (metoclopramide, domperidone and cis-
apride), H2-histamine receptor antagonists (cimetidine, 
famotidine and ranitidine), proton-pump inhibitors 
(omeprazole, rabeprazole, pantoprazole, lansoprazole, 
esomeprazole, dexlansoprazole, and immediate-release 
omeprazole), TLESR reducers and transient lower oe-
sophageal sphincter (LES) relaxation (baclofen) (7,8).
Laparoscopic Nissen fundoplication is the anti-reflux 
surgical treatment of choice (9). Surgery is indicated in 
case of medical therapy failure, an onset of complica-
tions derived from GORD such as peptic stenosis (10), 
intolerance to proton-pump inhibitors or patient prefer-
ence and the desire for a permanent solution from pa-
tients who wish to relieve their symptoms without con-
tinuing pharmacological treatment for life (11).
Amongst the extra-oesophageal symptoms of GORD, 
those relating to the oral cavity take on an important 
dimension. Although researchers have mainly focussed 
on hard tissue lesions, some researchers have attempted 
to establish relationships with other oral manifestations 
and GORD (12). Amongst these oral manifestations are 
dental sensitivity, bitter taste (13), a burning sensation 
in the mouth and pharynx, mouth ulcers (3) and ery-
thema on the palate and uvula (14,15). Few studies have 
been carried out on GORD’s role in tooth decay patho-
genesis or periodontal disease, although Katunari (16) 
and Song et al. (17) detected the presence of pathologi-
cal gingival changes in patients with GORD.
Other authors have focussed on the repercussions of sal-
ivary secretion on the oral state of patients with GORD 
because salivary secretion is a protective mechanism 
that helps to clear reflux acid from the oesophagus, thus 
reducing its harmful capacity on tissue (18). Several 
authors have studied the introduction of chewing gum 
into the normal treatment for GORD. Saliva production 
increases when the salivary gland is stimulated, which 
can compensate for low oral and oesophageal pH and 
prevent acid from reaching distal areas (19).
The aim of this study is to assess the improvement to 
oral extra-oesophageal manifestations in patients with 
GORD when using xylitol–malic acid tablets as a coad-
juvant for treatment along with omeprazole to stimulate 
salivary secretion.
Material and Methods 
This study was designed as an open, prospective, ran-
domized pilot study to evaluate the effects of stimulat-
ing salivary secretion on oral manifestations in patients 
with GORD (confirmed using positive result pH-metric 
tests) (20). The inclusion criteria for the study were as 
follows: the patient must have at least 16 remaining 
teeth (including upper front teeth); have no other situ-
ations favouring reflux and dental erosions, specifically 
chronic alcoholism, anorexia or bulimia, or excessive 
consumption of acid foods; be between 18 and 70 years 
of age, and not be taking any anti-inflammatory or an-
ticholinergic drugs. The presence or absence of dental 
erosions was not an exclusion factor.
Patients with GORD were randomly assigned using a 
random number assignation list (1:1) into two groups, 
to receive standard treatment of proton pump inhibitors 
(PPIs) or the experimental treatment of PPIs + saliva-
stimulating tablets. In all cases, double doses of omepra-
zole (40 mg) were administered once a day. This basic 
treatment was complemented by specific tablets for stim-
ulating salivary secretion, specifically of Xeros Den-
taid® (Dentaid, Spain), indicated for treating dry mouth. 
Each patient received a box of individually packaged 
Xeros Dentaid® tablets. They had to suck the tablets un-
til completely dissolved 3 times a day after main meals.
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to 7 episodes in the last week), as was RDQ, scored on 
2 dimensions: frequency (0 = never, 1 = less than once 
per week, 2 = once per week, 3 = between 2 and 3 times 
a week, 4 = from 4 to 6 times a week and 5 = daily epi-
sodes) and intensity (0 = no episodes, 1 = a very slight 
episode, 2 = a slight episode, 3 = a moderate episode, 4 = 
a moderate to severe episode and 5 = a severe episode).
This study was conducted in accordance with the ethi-
cal principles for medical research on humans, as de-
fined in the Declaration of Helsinki, and following the 
standards of good clinical practice. Approval was ob-
tained from the Ethical Committee of Virgen del Rocío 
and Virgen Macarena Hospital before commencing the 
study. Each patient was duly informed and required a 
signed informed consent form to take part in the study.
Statistical analysis was undertaken using the program 
SPSS 12.0. The Kolmogorov-Smirnov test was used to 
check for normality of the quantitative variables. Statis-
tical differences between the two groups were compared 
with qualitative variables using the chi-square test and 
with the Haberman post-hoc test applied. For numeri-
cal variables, analysis of variance (ANOVA) was used 
when a normal distribution was present, and the Mann-
Whitney U test was used with nonnormal distributions. 
To evaluate the progress of a variable over the different 
visits, the McNemar non-parametric test was used on 
dichotomous variables, Student’s t-tests were on numer-
ical variables with normal distributions and the Wilcox-
on test was used on numerical variables with nonnor-
mal distributions and on ordinal qualitative variables. 
Values of p < 0.05 were deemed statistically significant.
Results
Fourteen patients with GORD (Table 1) were studied: 
10 women and 4 men. Of these patients, 9 were younger 
than 55 years of age (5 of these patients took tablets), 
and 5 patients were over 55 years of age (2 took tablets). 
In total, 7 (50%) took the tablets and 7 (50%) did not.
Regarding the patients’ medical history (Table 2), 2 
(28.6%) presented a history of heart failure, 2 (28.6%) 
presented a history of high blood pressure, 1 (14.3%) 
presented thyroid problems and 2 (28.6%) presented 
other pathologies. Four patients presented anxiety and/
or depression, of whom 1 (7.1%) was not taking tablets 
and 3 (21.4%) were taking them.
The tablets were used as a coadjuvant treatment for 
GORD and its manifestations. The tablet being placed 
in the patient’s mouth stimulates salivary secretion, 
swallowing and, with this, oesophageal clearance. Sa-
liva may protect the oral cavity by diminishing the in-
flux of gastric material, neutralizing acids and creating 
a protective barrier in the mouth. Xeros Dentaid® tab-
lets are part of a range of products indicated for treating 
dry mouth. The tablets mainly comprise Xylitol (422.00 
mg), an alcohol derived from xylose. Its composition 
includes a small proportion of malic acid (28.58 mg), 
whose function is to further stimulate saliva flow, and 
sodium fluoride (0.58 mg). Regular use of xylitol, a sub-
stance not fermentable by oral bacteria, has been asso-
ciated with decreased tooth decay, with lower counts of 
S. mutans and greater plaque pH (21).
The patients underwent regular check-ups to assess the 
progress of their oral parameters, with the final check-
up being at six months. Initially, and for comparison 
between both study groups, the patients’ sex and age, 
medical history, service usage data and dental habits 
(time and reason for last visit to the dentist, frequency 
of visits to the dentist, frequency and type of brush-
ing, frequency and type of interdental cleaning, use of 
mouthwash and use of prosthesis) were recorded.
Extra-oesophageal manifestations of GORD were re-
corded (chronic cough, laryngitis, pharyngitis, asthma, 
idiopathic pulmonary fibrosis, sinusitis, recurrent otitis 
media, chronic hoarseness and chronic bronchitis) at the 
study’s outset and after six months, as were other odont-
ological variables (xerostomia, burning mouth, dysgeu-
sia, basal and stimulated salivary secretion, saliva pH, 
buffer capacity (by adding HCl, with 1 = low, 2 = medi-
um and 3 = high), O’Leary’s oral hygiene index, plaque 
index, calculus index, CAOD index, mucosal erythema 
index (with a score of 0 = normal, 1 = slight erythema, 
2 = moderate erythema and 3 = severe erythema), ul-
cerations (0 = absent, 1 = ulcers less than 0.25 cm in 
diameter and 2 = ulcers are larger .25 cm  in diameter) 
and dental wear (applying Smith and Knight’s dental 
wear index [TWI] (22), with a score of 0 to 4). Validated 
GerdQ questionnaires were also recorded (with each 
question scored on a scale of 0 to 3, with 0 = no episode 
in the last week, 1 =  1 episode in the last week, 2 = be-




Sign.Freq. Perc. Freq. Perc.
Woman 6 85.7 4 57.1
Man 1 14.3 3 42.9
Age Freq. Perc. Freq. Perc. Sign.
Up to 55 years 4 57.1 5 71.4
Over 55 years 3 42.9 2 28.6
Table 1: Initial data relating to age and sex in the sample studied.
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Use of tablet
 (n and % of positive cases) No Yes  Freq. Perc. Freq. Perc. Sign.
Medical history
Angina/ Infarction 0 0.0 0 0.0  
Murmur/ Valve 0 0.0 0 0.0  
Arrhythmia 0 0.0 0 0.0  
Heart failure 2 28.6 0 0.0  
High blood pressure 2 28.6 1 14.3  
Haemostatic disorder 0 0.0 0 0.0  
Cerebral vascular accident 0 0.0 0 0.0  
Epilepsy 0 0.0 0 0.0  
Asthma 0 0.0 0 0.0  
Pulmonary problems or cough 0 0.0 0 0.0  
Diabetes 0 0.0 0 0.0  
Thyroid 1 14.3 1 14.3  
Liver disorder 0 0.0 0 0.0  
Intestinal disorder 0 0.0 0 0.0  
Kidney disorder 0 0.0 0 0.0  
Cancer or leukaemia 0 0.0 0 0.0  
Infectious disease 0 0.0 0 0.0  
Immune system disorder 0 0.0 0 0.0  
Skin disorder 0 0.0 0 0.0  
Other diseases 2 28.6 2 28.6  
Anxiety and/or depression No 5 92.9 11 78.6  
Yes 1 7.1 3 21.4  
Taking antihypertensive drugs No 3 42.9 6 85.7  
Yes 4 57.1 1 14.3  
Taking anxiolytic - 
antidepressants- muscle relaxants
No 5 71.4 6 85.7  
Yes 2 28.6 1 14.3  
Time since last visit to the dentist
Less than one year 4 57.1 2 28.6  
Between 1 and 2 years 2 28.6 2 28.6  
Two or more years 1 21.4 3 42.9  
Reason for visiting the dentist
Check-up 3 42.9 2 28.6  
Cleaning 4 57.1 2 28.6  
Fillings 1 14.3 2 28.6  
Extractions 2 28.6 1 14.3  
Other treatment 1 14.3 2 28.6  
Frequency of dental visits On demand 2 28.6 4 57.1  
Between 0.5 and 1.5 times / year 5 71.4 3 42.9  
Brushing frequency (times per day)
Once 3 42.9 2 28.6  
Between 1 and 2 times 2 28.6 3 42.9  
More than twice 2 28.6 2 28.6  
Type of toothbrush Manual 5 71.4 4 57.1  
Electric (or both) 2 28.6 3 42.9  
Use of floss or interdental brush Yes 2 28.6 2 28.6  
No 5 71.4 5 71.4  
Frequency of use of floss or 
interdental brush
Daily 0 0.0 1 100.0  
Twice or three times / week 1 100.0 0 0.0  
Use of mouthwash Yes 4 57.1 2 28.6  
No 3 42.9 5 57.1  
Frequency of use of mouthwash
Daily 3 60.0 2 50.0  
Once or twice / week 0 0.0 2 50.0  
Occasionally 2 40.0 0 0.0  
Prosthesis user Yes 3 21.4 3 23.1  
No 11 78.6 10 76.9  
Table 2: Medical history, oral habits and dental variables in the sample studied.
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Regarding the time since their last visit to the dentist, 
among those who had last visited a dentist less than 1 
year ago, 4 patients (57.1%) were not taking the tab-
lets, and 2 (28.6%) were. For those from whom it had 
been between and 1 and 2 years since the last visit, 2 
(28.6% of patients) were not taking the tablets, and 3 
(42.9%) patients were. Regarding the reason for visit-
ing the dentist, the most common one was for scaling 
and dental prophylaxis, with 4 (57.1%) of these patients 
not taking the tablets and 2 (28.6%) who were.
The study groups were comparable, in terms of epi-
demiological and socioeconomic variables, since no 
significant differences were found.
Regarding the variables studied, the following data 
were found at the outset. With reference to extra-
oesophageal manifestations (Table 3), chronic cough 
was presented by 1 (14.3%) patient who was not taking 
the tablets and 4 (57.1%) patients who were (p < 0.05); 
with regard to chronic hoarseness, it was presented by 
3 (42.9%) patients who were taking the tablets (p < 
0.05). The emergence of laryngitis, pharyngitis, asth-
ma, pulmonary fibrosis, sinusitis or otitis media had no 
significant relationship with taking the xylitol–malic 
acid tablets.
Regarding the dental history variables (Table 3), no 
significant differences were found between the pa-
tients taking xylitol–malic acid and those who were 
not taking it in terms of the variables identifying the 
presence of xerostomia, dysgeusia or burning mouth; 
those referring to pH, basal and stimulated saliva or 
saliva-buffering capacity; the indices for plaque, cal-
culus, CAOD index or mucosal erythema index; num-
ber of ulcers; or tooth wear.
Regarding the GerdQ questionnaire, on average, the 
results for a burning sensation behind the sternum 
were 4.00 ± 0.00 for the group not taking the tablets 
and 2.57 ± 1.27 for the patients who were taking the 
tablets (p < 0.05). No significant differences were 
found between the study groups for any of the other 
aspects contemplated in this index (Table 3).
Regarding the RDQ (Frequency) index, significant 
differences (p < 0.01) between both groups were only 
found at the start of the study in relation to localized 
burning behind the sternum (6.00 ± 0.00 for patients 
not taking the tablets versus 3.75 ± 2.07 for those who 
were), stomach acidity (6.00 ± 0.00 for patients not tak-
ing the tablets versus 3.14 ± 2.27 for those who were) 
(p < 0.01) and gastric reflux (4.00 ± 2.24 for patients 
not taking the tablets versus 1.43 ± 1.13 for patients 
who were) (p < 0.05) (Table 3).
In relation to the RDQ (Intensity) index, the 2 groups 
only had significant differences (p < 0.01) in con-
nection with burning behind the sternum (5.29 ± 0.76 
for patients not taking the tablets versus 3.43 ± 2.07 
for those who were), stomach acidity (5.29 ± 0.76 in 
patients not taking the tablets  versus 2.71 ± 1.89 for 
those who were taking xylitol–malic acid) (p < 0.01) 
and gastric reflux (3.29 ± 2.14 in patients not taking 
the tablets versus 1.57 ± 1.51 in those who were taking 
xylitol–malic acid) (p < 0.05) (Table 3).
Between the first and last visit, after 6 months, both 
groups had similar initial values for their socioeco-
nomic aspects and medical and odontological history. 
Significant differences were only found in some values 
for GerdQ and RDQ. Notwithstanding, this difference 
justified why the analysis of both groups regarding the 
studied values should not be carried against each the 
other; rather, we focused on the improvement in each 
group, taking as the first-visit values as the reference 
point.
No significant differences between the patients taking 
the xylitol–malic acid tablets and the patients not tak-
ing them were established with respect to the majority 
of the studied variables, when the first-visit data were 
compared with the final-visit data (Table 4). No sig-
nificant differences were found after 6 months in the 
extra-oesophageal or dental history manifestations, 
the CAOD index evaluation, the dental wear evalua-
tion or the mucosal erythema index. Regarding saliva 
analysis, the group that did take the xylitol–malic acid 
tablets had increased buffer capacity (up to 2.71 ± 0.49 
from values starting at 2.17 ± 0.41), a statistically sig-
nificant difference (p < 0.05), while the group that did 
not take the tablets did not obtain any improvement in 
this parameter.
Regarding the GerdQ and RDQ questionnaires (Table 
4), several symptoms showed improvements. The im-
provement to the burning sensation behind the ster-
num (GErdQ) was similar between the 2 groups, at the 
same percentage. At the end of the study, the group not 
taking the tablets presented a mean of 50% of the first-
visit value for this value, compared with 50.19% for 
the group taking the tablets (p < 0.05 in both cases). 
Regarding the same sensation but measured with RDQ 
(Frequency) and RDQ (Intensity), the improvement in 
both groups was similar in both groups and statisti-
cally significant (p < 0.05). On the RDQ (Frequency) 
measurement, the mean value at week 3 was 42.83% of 
the initial one for the group not taking the tablets, ver-
sus 40.05% for the other group. Similar improvement 
percentages were obtained on the RDQ (Intensity) for 
the same variable (p < 0.05).
The results for the stomach acidity variable in the RDQ 
(Frequency) and RDQ (Intensity) behaved similarly. 
Both study groups showed statistically significant im-
provements, with a similar intensity, when comparing 
data from the first and final visits (p < 0.05). The rest 
of the variables did not present any statistically signifi-
cant differences between the first- and last-visit values 
(Table 4).
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Use of tablet
(n and % of positive cases)
No Yes
Sign.
Freq. Perc. Freq. Perc.
Extra-oesophageal manifestations
Chronic cough 1 14.3 4 57.1 Quasi
Laryngitis 1 14.3 2 28.6  
Pharyngitis 2 28.6 3 42.9  
Asthma 1 14.3 1 14.3  
Idiopathic pulmonary fibrosis 0 0.0 0 0.0  
Sinusitis 0 0.0 0 0.0  
Recurrent otitis media 0 0.0 0 0.0  
Chronic hoarseness 0 0.0 3 42.9 Quasi
Chronic bronchitis 0 0.0 1 14.3  
Dental history   
Xerostomia 6 85.7 4 57.1  
Burning mouth 2 21.4 2 21.4  
Dysgeusia 2 21.4 2 21.4  
Saliva and pH
Basal saliva (ml) 2.06 1.42 3.33 1.18  
Stimulated saliva (ml) 6.70 3.13 8.30 3.81  
pH basal saliva 6.71 0.27 6.83 0.26  
pH stimulated saliva 7.00 0.00 7.08 0.20  
Saliva buffering capacity 2.14 0.38 2.17 0.41  
O´Leary oral hygiene index and 
calculus index
Plaque index 1.43 0.53 1.57 0.79  
Calculus index 1.00 1.00 0.71 1.11  
CAOD index and associated variables
Caries 0.71 1.25 1.86 1.35 Quasi
Missing 6.29 3.99 3.57 3.46  
Filled 4.57 6.83 6.57 3.55  
Teeth 21.71 3.99 24.43 3.46  
CAOD index 0.41 0.22 0.43 0.19  
Mucosal erythema index and ulcers
Uvula 1.14 0.90 1.57 0.79  
Soft palate 0.57 0.79 1.00 0.82  
Ulcerations 0.00 0.00 0.29 0.76  
Tooth wear
Mean incisor wear 2.43 1.27 2.86 0.90  
Mean canine wear 1.86 0.38 1.86 0.69  
Mean premolar and molar wear 1.43 1.90 2.14 1.86  
GerdQ
Burning sensation behind sternum 4.00 0.00 2.57 1.27 <0.05
Stomach content reflux 2.86 1.35 1.86 1.46  
Stomach-ache 1.86 1.46 1.43 1.13  
Has had nausea 2.14 1.46 2.00 1.41  
Sleep difficulties 2.29 1.60 1.14 0.38  
Additional medication for burning 1.60 1.34 1.00 0.00  
RDQ (Frequency)
Burning behind sternum 6.00 0.00 3.57 2.07 <0.01
Pain behind sternum 1.71 1.89 1.00 0.00  
Burning in stomach 6.00 0.00 3.14 2.27 <0.01
Stomach-ache 2.43 2.44 1.00 0.00  
Bitter taste in mouth 3.71 2.56 2.43 2.44  
Stomach content reflux 4.00 2.24 1.43 1.13 <0.05
RDQ (Intensity)
Burning behind sternum 5.29 0.76 3.43 2.07 <0.01
Pain behind sternum 1.57 1.51 1.00 0.00  
Burning in stomach 5.29 0.76 2.71 1.89 <0.01
Stomach-ache 2.14 1.95 1.00 0.00  
Bitter taste in mouth 3.29 2.21 1.71 1.25  
Stomach content reflux 3.29 2.14 1.57 1.51 Quasi
Table 3: Extra-oesophageal manifestations.
e824
Med Oral Patol Oral Cir Bucal. 2020 Nov 1;25 (6):e818-26. Salivary stimulation with xylitol-malic acid tablets in GORD
(% of positive cases)
Without tablets With tablets
Last visit First visit Sig. Last visit First visit Sig.
Extra-oesophageal 
manifestations
Chronic cough 14.3 14.3  57.1 57.1  
Laryngitis 0.0 14.3  28.6 28.6  
Pharyngitis 14.3 28.6  42.9 42.9  
Asthma 0.0 14.3  14.3 14.3  
Idiopathic pulmonary fibrosis 0.0 0.0  0.0 0.0  
Sinusitis 0.0 0.0  0.0 0.0  
Recurrent otitis media 0.0 0.0  0.0 0.0  
Chronic hoarseness 0.0 0.0  57.1 42.9  
Chronic bronchitis 0.0 0.0  14.3 14.3  
Dental history   
Xerostomia 100.0 85.7  14.3 57.1  
Burning mouth 14.3 28.6  0.0 0.0  
Dysgeusia 12.5 28.6  0.0 0.0  
Saliva and pH
Basal saliva (ml) 2.49 ± 1.68 2.06 ± 1.42  4.09 ± 1.08 3.33 ± 1.18  
Stimulated saliva (ml) 7.31 ± 4.33 6.70 ± 3.13  8.99 ± 4.05 8.30 ± 3.81  
pH basal saliva 6.79 ± 0.27 6.71 ± 0.27  7.00 ± 0.00 6.83 ± 0.26  
pH stimulated saliva 7.07 ± 0.19 7.00 ± 0.00  7.21 ± 0.27 7.08 ± 0.20  
Saliva buffering capacity 2.14 ± 0.38 2.14 ± 0.38  2.71 ± 0.49 2.17 ± 0.41 <0.05
O´Leary oral hy-
giene index and 
calculus index
Plaque index 1.43 ± 0.53 1.43 ± 0.53  1.14 ± 1.07 1.57 ± 0.79  
Calculus index 0.71 ± 0.83 1.00 ± 1.00  0.71 ± 0.76 0.71 ± 1.11  
CAOD index and 
associated varia-
bles
Caries 0.86 ± 1.22 0.71 ± 1.25  2.00 ± 1.53 1.86 ± 1.35  
Missing 6.71 ± 4.89 6.29 ± 3.99  3.71 ± 3.59 3.57 ± 3.46  
Filled 4.57 ± 6.83 4.57 ± 6.83  6.57 ± 3.55 6.57 ± 3.55  
Teeth 21.71 ± 3.99 21.71 ± 3.99  24.43 ± 3.46 24.43 ± 3.46  
CAOD index 0.42 ± 0.23 0.41 ± 0.22  0.44 ± 0.20 0.43 ± 0.19  
Mucosal erythema 
index and ulcers
Uvula 1.00 ± 0.58 1.14 ± 0.90  1.00 ± 0.58 1.57 ± 0.79  
Soft palate 0.00 ± 0.00 0.57 ± 0.79  0.71 ± 0.76 1.00 ± 0.82  
Ulcerations 0.00 ± 0.00 0.00 ± 0.00  0.14 ± 0.38 0.29 ± 0.76  
Tooth wear
Mean incisor wear 2.86 ± 1.46 2.43 ± 1.27  2.71 ± 0.95 2.86 ± 0.90  
Mean canine wear 2.00 ± 1.29 1.86 ± 0.38  1.71 ± 1.11 1.86 ± 0.69  
Mean premolar and molar wear 1.14 ± 1.95 1.43 ± 1.90  2.00 ± 2.00 2.14 ± 1.86  
GerdQ
Burning sensation behind sternum 2.00 ± 1.41 4.00 ± 0.00 <0.05 1.29 ± 0.76 2.57 ± 1.27 <0.05
Stomach content reflux 1.86 ± 1.22 2.86 ± 1.35  1.57 ± 1.13 1.86 ± 1.46  
Stomach-ache 1.86 ± 1.46 1.86 ± 1.46  1.14 ± 0.38 1.43 ± 1.13  
Has had nausea 2.00 ± 1.29 2.14 ± 1.46  1.57 ± 1.13 2.00 ± 1.41  
Sleep difficulties 1.43 ± 0.79 2.29 ± 1.60  1.14 ± 0.38 1.14 ± 0.38  
Additional medication for burning 1.71 ± 1.25 1.60 ± 1.34  1.00 ± 0.00 1.00 ± 0.00  
RDQ (Frequency)
Burning behind sternum 2.57 ± 2.15 6.00 ± 0.00 <0.05 1.43 ± 1.13 3.57 ± 2.07 <0.05
Pain behind sternum 1.00 ± 0.00 1.71 ± 1.89  1.00 ± 0.00 1.00 ± 0.00  
Burning in stomach 2.29 ± 1.21 6.00 ± 0.00 <0.05 1.43 ± 1.13 3.14 ± 2.27 <0.05
Stomach-ache 2.29 ± 2.21 2.43 ± 2.44  1.43 ± 1.13 1.00 ± 0.00  
Bitter taste in mouth 3.00 ± 2.24 3.71 ± 2.56  1.00 ± 0.00 2.43 ± 2.44  
Stomach content reflux 2.43 ± 1.99 4.00 ± 2.24  1.71 ± 1.89 1.43 ± 1.13  
RDQ (Intensity)
Burning behind sternum 2.29 ± 1.89 5.29 ± 0.76 <0.05 1.29 ± 0.76 3.43 ± 2.07 <0.05
Pain behind sternum 1.00 ± 0.00 1.57 ± 1.51  1.00 ± 0.00 1.00 ± 0.00  
Burning in stomach 2.00 ± 1.91 5.29 ± 0.76 <0.05 1.29 ± 0.76 2.71 ± 1.89 <0.05
Stomach-ache 1.86 ± 1.86 2.14 ± 1.95  1.00 ± 0.00 1.00 ± 0.00  
Bitter taste in mouth 3.00 ± 2.24 3.29 ± 2.21  1.00 ± 0.00 1.71 ± 1.25  
Stomach content reflux 2.86 ± 2.41 3.29 ± 2.14  1.71 ± 1.25 1.57 ± 1.51  
Table 4: Comparison of variables between first and last visit in study groups.
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Discussion
The two groups had significant differences in terms of 
the xerostomia variable. Upon completing the study, 
all of the patients in the control group (100%) stated 
that they had suffered xerostomia, compared to only 
2 (14.3%) in the group taking the tablets. This finding 
implies that consumption of chewable tablets increases 
salivary secretion.
Lapiedra et al. (23) reached the same conclusion in a 
study on 34 patients who were divided into 2 groups; 
1 group was administered saliva-stimulating tablets 
containing xylitol, and the other control group was 
provided sorbitol tablets for 1 week. After resting for 
1 week, the groups were inverted, with the study group 
receiving sorbitol tablets and vice versa. In this study, 
xerostomia was measured using a subjective question-
naire, and both groups showed decreased xerostomia as 
compared with the start of the study, but only the study 
group taking xylitol tablets had a significant decrease, 
as compared with the group taking sorbitol (23).
The difference between the work by Lapiedra et al. 
and the present study is that, in this study, the amount 
of saliva was collected and measured (both basal and 
stimulated) using paraffin pastilles, while in the study 
by Lapiedra et al., it was quantified using a question-
naire (23). Another difference between this study and 
the one carried out by Lapiedra et al. (23) was that in the 
latter, the authors administered 4 xylitol tablets per day, 
compared to 3 in this study.
In another study by Peres et al. (24) undertaken on 27 
patients, using chewable maltose tablets resulted in in-
creased compared with baseline measurements. Fur-
thermore, 2 literature reviews carried out by Brosky et 
al. (25) and by Plemons (26) claim that chewable tablets 
increase salivary secretion in patients with xerostomia, 
thus improving their quality of life.
The present study also observed that the saliva-buff-
ering capacity increased significantly on the final visit 
among patients treated with tablets, compared to those 
who were not treated with them. One can deduce that 
the tablets not only increased the amount of saliva but 
also improved its chemical properties and acid-neutral-
izing buffer capacity.
This finding corroborates the conclusions of Kharev-
ich et al. (27), who, in a pilot study on 10 patients, also 
observed increased saliva-buffering capacity, which re-
duced its acidity and minimised xerostomia, as in this 
study with xylitol–malic acid tablets.
The present study also found some improvement among 
the patients treated with tablets with respect to bitter 
taste in the mouth because those who did not take the 
xylitol–malic acid tablets experienced bitter taste more 
intensely and more frequently. Note that bitter taste in 
the mouth is one of the most characteristic symptoms of 
GORD, (28,29) so much so that although certain drugs 
objectively improve the disease’s symptoms (such as 
proton pump inhibitors), they do not prevent patients 
from experiencing a bitter taste in their mouth, with this 
symptom persisting despite the treatment (30). For this 
reason, it is very important that the xylitol–malic acid 
tablets used in this study relieved this unpleasant extra-
oesophageal symptom of GORD.
Summarising the results provided by this study, xylitol–
malic acid tablets (Xeros®) demonstrated the capacity 
to improve quality of life in patients with GORD by re-
ducing xerostomia, improving saliva-buffering capacity 
and relieving regurgitation and the sensation of gastric 
and retrosternal burning.
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